Laboratoire de Spectrométrie de Masse des Interactions et des Systèmes (LSMIS), UMR 7140 (Unistra-CNRS), Université de Strasbourg, France.
School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Centre Médical Universitaire (CMU), Rue Michel-Servet 1, 1206 Geneva, Switzerland.
Talanta. 2018 Feb 1;178:530-537. doi: 10.1016/j.talanta.2017.09.083. Epub 2017 Oct 2.
Characterization of therapeutic proteins represents a major challenge for analytical sciences due to their heterogeneity caused by post-translational modifications (PTM). Among these PTM, glycosylation which is possibly the most prominent, require comprehensive identification because of their major influence on protein structure and effector functions of monoclonal antibodies (mAbs). As a consequence, glycosylation profiling must be deeply characterized. For this application, several analytical methods such as separation-based or MS-based methods, were evaluated. However, no CE-ESI-MS approach has been assessed and validated. Here, we illustrate how the use of CE-ESI-MS method permits the comprehensive characterization of mAbs N-glycosylation at the glycopeptide level to perform relative quantitation of N-glycan species. Validation of the CE-ESI-MS method in terms of robustness and reproducibility was demonstrated through the relative quantitation of glycosylation profiles for ten different mAbs produced in different cell lines. Glycosylation patterns obtained for each mAbs were compared to Hydrophilic Interaction Chromatography of 2-aminobenzamide labelled glycans with fluorescence detector (HILIC-FD) analysis considered as a reference method. Very similar glycoprofiling were obtained with the CE-ESI-MS and HILIC-FD demonstrating the attractiveness of CE-ESI-MS method to characterize and quantify the glycosylation heterogeneity of a wide range of therapeutic mAbs with high accuracy and precision.
由于治疗性蛋白质的不均一性是由翻译后修饰(PTM)引起的,因此其特征描述对分析科学来说是一个重大挑战。在这些 PTM 中,糖基化可能是最突出的一种,由于其对蛋白质结构和单克隆抗体(mAbs)效应功能的主要影响,需要进行全面鉴定。因此,必须对糖基化谱进行深入分析。为此,评估了几种分析方法,例如基于分离或基于 MS 的方法。但是,尚未评估和验证 CE-ESI-MS 方法。在这里,我们展示了如何使用 CE-ESI-MS 方法在糖肽水平上全面表征 mAb 的 N-糖基化,以进行 N-聚糖种类的相对定量。通过对在不同细胞系中生产的十种不同 mAb 的糖基化谱进行相对定量,证明了 CE-ESI-MS 方法在稳健性和重现性方面的验证。将每种 mAb 的获得的糖基化模式与以荧光检测器(HILIC-FD)分析为参考方法的 2-氨基苯甲酰胺标记聚糖的亲水相互作用色谱(HILIC-FD)分析进行了比较。CE-ESI-MS 和 HILIC-FD 获得了非常相似的糖基化谱,证明了 CE-ESI-MS 方法在表征和定量广泛的治疗性 mAb 的糖基化异质性方面具有吸引力,具有高精度和高精确度。